Photorelease of a metal-binding pharmacophore from a Ru(II) polypyridine complex.

ABSTRACT: The adoption of compounds that target metalloenzymes comprises a relatively low (<5%) percentage of all FDA approved therapeutics. Metalloenzyme inhibitors typically coordinate to the active site metal ions and therefore contain ligands with charged or highly polar functional groups. While these groups may generate highly water-soluble compounds, this functionalization can also limit their pharmacological properties. To overcome this drawback, drug candidates can be formulated as prodrugs. While a variety of protecting groups have been developed, increasing efforts have been devoted towards the use of caging groups that can be removed upon exposure to light to provide spatial and temporal control over the treatment. Among these, the application of Ru(ii) polypyridine complexes is receiving

SUBMITTER: Karges J 

PROVIDER: S-EPMC7944940 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature